Researchers can use KLOW Blend to study mechanisms of gut swelling, examine the role of barrier dysfunction in IBD pathogenesis, and assess possible treatment strategies
These include promoting the formation of new blood vessels, supporting collagen production, regulating inflammatory responses, and helping repair damaged tissues
Average weight loss in the treatment group was 13.6% body weight, compared to 2.4% in the placebo group
Flavonoid metabolism: the interaction of metabolites and gut microbiota
The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme [of CT-388] as we advance to phase III trials" Dr Levi Garraway, PhD, Roches Chief Medical Officer and Head of Global Product Development, said: We are pleased to see such meaningful weight loss in people treated with CT-388